AIP
ASND icon

Arrowpoint Investment Partners’s Ascendis Pharma A/S ASND Stock Holding History

Arrowpoint Investment Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,828
Closed -$2.71M – 133
2026
Q1 		$2.71M Buy
11,828
+8,831
+295% +$1.98M 2.4% 11
2025
Q4 		$639K Buy
+2,997
New +$619K 0.09% 60

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Arrowpoint Investment Partners's ASND Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 11,828 shares — an estimated $2.71M sold.

Arrowpoint Investment Partners first reported a position in ASND in Q4 2025 and held it in 2 quarters. The position peaked at $2.71M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Arrowpoint Investment Partners reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 11,828 Ascendis Pharma A/S shares in Q2 2026, an estimated $2.71M.
  • Arrowpoint Investment Partners first reported a position in Ascendis Pharma A/S in Q4 2025 and held it in 2 quarters.
  • Arrowpoint Investment Partners's Ascendis Pharma A/S position peaked at $2.71M in Q1 2026.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.